Emricasan (IDN-6556)

製品コードS7775 バッチS777506

印刷

化学情報

Synonyms

PF 03491390, PF-03491390

Storage
(From the date of receipt)

3 years -20°C powder
1 years -80°C in solvent

化学式

C₂₆H₂₇F₄N₃O₇

分子量

569.50

CAS No.

254750-02-2

Solubility (25°C)*

体外

DMSO

100 mg/mL (175.59 mM)

Ethanol

100 mg/mL (175.59 mM)

Water

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension

CMC-NA

≥5mg/ml

Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Emricasan (IDN-6556, PF 03491390, PF-03491390) is a potent irreversible pan-caspase inhibitor. Emricasan is an inhibitor of Zika virus infection.
in vitro	Emricasan (IDN-6556), also called PF-03491390, is an inhibitor of activated caspases with sub- to nanomolar activity in vitro. It shows neuroprotective activity for hNPCs but does not suppress ZIKV replication^[2].
in vivo	In the murine NASH model, stellate cell activation and hepatic fibrogenesis are attenuated by administration of Emricasan (IDN-6556), a pan-caspase inhibitor^[1]. It decreases liver injury but not metabolic derangement in NASH and also ameliorates inflammation. This compound is currently being evaluated in phase 2 clinical trials for the reduction of hepatic injury and liver fibrosis caused by chronic HCV infection^[2].

プロトコル(参考用のみ)

細胞アッセイ	細胞株	Astrocytes
	濃度	9 μM
	反応時間	1 h
	実験の流れ	Astrocytes are mock-infected, treated with DMSO or treated with 2 μM niclosamide, 92 μM PHA-690509, 9 μM emricasan (IDN-6556), or a combination of 92 μM PHA-690509 and this compound for 1 h before infection with PRVABC59 (MOI = 0.5). Cells are fixed 24 h after infection and stained for ZIKVE and nuclei.
動物実験	動物モデル	C57BL/6J mice
	投薬量	0.3mg/kg/day
	投与方法	i.g.

参考

https://pubmed.ncbi.nlm.nih.gov/24750664/
https://pubmed.ncbi.nlm.nih.gov/27571349/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

SIGLEC12 mediates plasma membrane rupture during necroptotic cell death [ Nature, 2025, 10.1038/s41586-025-09741-1]	PubMed: 41225007
Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia [ Cell, 2025, S0092-8674(25)01233-4]	PubMed: 41265435
WNK1 mediates M-CSF-induced macropinocytosis to enforce macrophage lineage fidelity [ Nat Commun, 2025, 16(1):4945]	PubMed: 40436823
RIPK1 autophosphorylation at S161 mediates cell death and inflammation [ J Exp Med, 2025, 222(12)e20250279]	PubMed: 40996439
IFNγ augments TKI efficacy by alleviating protein unfolding stress to promote GSDME-mediated pyroptosis in hepatocellular carcinoma [ Cell Death Dis, 2025, 16(1):512]	PubMed: 40645933
Establishment of bovine extraembryonic endoderm stem cells enables efficient blastoid formation [ Cell Rep, 2025, 44(6):115707]	PubMed: 40402743
Pan-caspase inhibitors induce secretion of HIV-1 latency reversal agent lymphotoxin-alpha from cytokine-primed NK cells [ Cell Death Discov, 2025, 11(1):44]	PubMed: 39905001
Neuroligin-3 R451C induces gain-of-function gene expression in astroglia in an astroglia-enriched brain organoid model [ Cell Regen, 2025, 14(1):1]	PubMed: 39775628
Morphogen-guided neocortical organoids recapitulate regional areal identity and model neurodevelopmental disorder pathology [ bioRxiv, 2025, 2025.09.02.672952]	PubMed: 40950130
Protocol for purifying primitive neural progenitors by fractional passaging to generate astroglia-enriched cerebral organoid [ STAR Protoc, 2025, 6(4):104142]	PubMed: 41091601

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。